Skip to content
WeighLab
Menu
Ranked #27 · Grade B−

Curex review

A discounted first month ($49-$149) steps up to a 'starting at $199' ongoing rate — real, but not the flat, fully-disclosed price the headline implies, and California loses the injectable route entirely.

Visit Curex Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. See our disclosure.
Semaglutide
$199/mo Starting (first month $49)
Tirzepatide
$199/mo Starting (first month $149)
Coverage
All 50 states (California: oral tablet only, no injectable)
Brand-name
Compounded only

Semaglutide · modeled / year

$2,388

Tirzepatide · modeled / year

$2,388

The Index scorecard

Curex scored on our six Cost-Efficiency Index factors. See the methodology.

Normalized Cost/Month78/100
Price Transparency75/100
Nationwide Access90/100
Formulation Options84/100
Clinical Oversight80/100
Contract Flexibility80/100

Where the value is

  • Discounted first month well below the ongoing rate — $49 for semaglutide, $149 for tirzepatide
  • Nationwide enrollment (all 50 states) plus an oral/sublingual route as an alternative to injections
  • 365-day money-back guarantee and a full refund if never prescribed
  • LegitScript-certified badge displayed on-site

The tradeoffs

  • The '$199/mo' figure is labeled 'Starting,' not flat — no dose-by-dose price table is published, so the real cost at a higher maintenance dose is unverified
  • California residents cannot get the injectable route at all — oral tablets only, despite the 'all 50 states' enrollment claim
  • Named clinical leadership is disclosed in the context of Curex's original allergy-clinic business, not confirmed as GLP-1-specific prescribers
  • No FDA-approved brand-name access

The bottom line

Best for: People who want a low-cost first month, an oral option, and a verified pharmacy nationwide, and don't need a dose-by-dose price table before signing up. A discounted first month ($49-$149) steps up to a 'starting at $199' ongoing rate — real, but not the flat, fully-disclosed price the headline implies, and California loses the injectable route entirely.

Ranked #27 of 529 providers on the Cost-Efficiency Index — see our #1 pick, CoreAge Rx, for comparison.

Compare with other providers

All 528 other providers we've modeled, in Cost-Efficiency Index order. See the ranked alternatives to Curex.

The 24 programs nearest this one

Pricing, states and verification reflect Curex's public disclosures at last review; the Cost-Efficiency Index is our editorial judgment per the methodology. Prices change — confirm on Curex's site. Not medical advice; see our disclosure.

← Back to the value leaderboard